Endocrine response and resistance in breast cancer: A role for the transcription factor fos

International Journal of Cancer

Volumn 84, Issue 1, 1999, Pages 54-61

  Gee, Julia M W ^a   Willsher, Peter C ^b   Kenny, Frances S ^b   Robertson, John F R ^b   Pinder, Sarah E ^b   Ellis, Ian O ^b   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY KI 67; PROTEIN C FOS; TAMOXIFEN; TRANSCRIPTION FACTOR;

AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CELL PROLIFERATION; ENDOCRINE SYSTEM; GENE EXPRESSION; HORMONE SENSITIVITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE C FOS; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; ENDOCRINE SYSTEM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MITOTIC INDEX; PROTO-ONCOGENE PROTEINS C-FOS; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032940738     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990219)84:1<54::AID-IJC11>3.0.CO;2-X     Document Type: Article

References (58)

1. AGADIR, A., SHEALY, Y.F., HILL, D.L. and ZHANG, X., Retinyl methyl ether down-regulates activator protein-1 transcriptional activation in breast cancer cells. Cancer Res., 57, 3444-3450 (1997).
2. ARTEAGA, C.L. and HOLT, J.T., Tissue targeted anti-sense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res., 56, 1098-1103 (1996).
3. ASTRUC, M.E., CHABRET, C. BALI, P., GAGNE, D. and PONS, M., Prolonged treatment or breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. Endocrinology, 136, 824-832 (1995).
4. BADIA, E., DUCHESNE, M.J., ASTRUC, M., FUENTES, M., GAGNE, D., NICOLAS, J.C. and PONS, M., Modulation of cellular response expression during prolonged treatment with antiestrogens. C.R. Acad. Sci.(Paris), 189, 755-764 (1995).
5. BLAND, K.I., KONSTADOULAKIS, M.M., VEZERIDIS, M.P. and WANEBO, H.J., Oncogene protein co-expression. Value of Ha-Ras, c-myc, c-Fos, and p53 as prognostic discriminants for breast carcinoma. Ann. Surg., 221, 706-720 (1995).
6. BRITISH BREAST GROUP, Assessment of response to treatment in advanced breast cancer. Lancet, 2, 38-39 (1974).
7. CLARKE, R.B., LAIDLAW, I.J., JONES, L.J., HOWELL, A. and ANDERSON, E., Effect of tamoxifen on Ki-67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Brit. J. Cancer, 67, 606-611 (1993).
8. DANOVA, M., PELLICCIARI, C., ZIBERA, C., MANGIAROTTI, R., GIBELLI, N., GIORDANA, M., WANG, E., MAZZINI, G. and RICCARDI, A., Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Flow cytometric analyses of DNA content, BrdU labeling, Ki-7, PCNA and statin expression. Ann. N.Y. Acad. Sci., 698, 174-181 (1993).
9. DAVIDSON, N.E., PRESTIGIACOMO, L.J. and HAHM, H.A., Induction of jun gene family members by transforming growth factor-alpha but not 17-beta-estradiol in human breast cancer cells. Cancer Res., 53, 291-297 (1993).
10. DUAN, R., PORTER, W. and SAFE, S., Estrogen-induced c-fos protoonogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology, 139, 1981-1990 (1998).
11. DUMONT, J.A., BITONTI, A.J., WALLACE, C.D., BAUMANN, R.J., CASHMAN, E.A. and CROSS-DOERSEN, D.E., Progression of MCF-7 breast cancer cells to antiestrogen resistant phenotype is accompanied by elevated levels of AP-1 DNA binding activity. Cell Growth Differentiation, 7, 351-359 (1996).
12. ELLIS, P.A. and 12 OTHERS, Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int. J. Cancer, 72, 608-613 (1997).
13. ELSTON, C.W. and ELLIS, I.O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19, 403-410 (1991).
14. ERDOS, G., LEE, Y.J., CHO, J.M. and CORRY, P.M., Heat-induced bF gf gene expression in the absence of heat shock element correlates with enhanced AP-1 binding activity. J. cell. Physiol., 164, 404-413 (1995).
15. FANJUL, A.N., BOUTERFA, H., DAWSON, M. and PFAHL, M., Potential role for retinoic acid receptor gamma in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Res., 56, 1571-1577 (1996).
16. FERNANDO, I.N., TITLEY, J.C., POWLES, T.J., DOWSETT, M., TROTT, P.A., ASHLEY, S.E., FORD, H.T. and ORMEROD, M.G., Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen. Brit. J. Cancer, 70, 1211-1216 (1994).
17. FONTANA, J.A., Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp. cell. Biol., 55, 136-144 (1987).
18. GEE, J.M.W., ELLIS, I.O., ROBERTSON, J.F.R., WILLSHER, P., MCCLELLAND, R.A., HEWITT, K.N., BLAMEY, R.W. and NICHOLSON, R.I., Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer, 64, 269-273 (1995).
19. GEE, J.M.W., MCCLELLAND, R.A. and NICHOLSON, R.I., Growth factors and endocrine sensitivity in breast cancer. In J.R. Pasqualini and B.S. Katzenellenbogen (eds.), Hormone-dependent cancer, pp. 169-197, M. Dekker, New York (1996).
20. HAYWARD, J.L., CARBONNE, P.P., HEUSON, J.C., KUMAOKA, S. and RUBENS, R., Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer, 39, 1289-1293 (1977).
21. HENNIGAN, R.F., HAWKER, K.L. and OZANNE, B.W., Fos transformation activates genes associated with invasion. Oncogene, 9, 3591-3600 (1994).
22. HOLT, J.T., ARTEAGA, C.B., ROBERTSON, D. and MOSES, H.L., Clinical protocol: gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA. Hum. Gene Ther., 7, 1367-1380 (1996).
23. HUANG, C., MA, W.-Y., DAWSON, M.I., RINCON, M., FLAVELL, R.A. and DONG, Z., Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc. nat. Acad. Sci. (Wash.), 94, 5826-5830 (1997).
24. HYDER, S.M., STANCEL, G.M., NAWAZ, Z., MCDONNELL, D.P. and LOOSE-MITCHELL, D.S., Identification of an estrogen response element in the 3′-flanking region of the murine c-fos protooncogene. J. biol. Chem., 267, 18047-18054 (1992).
25. JOHNSTON, S.R., MACLENNAN, K.A., SACKS, N.P., SALTER, J., SMITH, I.E. and DOWSETT, M., Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Europ. J. Cancer, 30A, 1663-1669 (1994).
26. KATO, S., ENDOH, H., MASUHIRO, Y., KITAMOTO, T., UCHIYAMA, S., SASAKI, H., MASUSHIGE, S., GOTOH, Y., NISHIDA, E. and KAWASHIMA, H., Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science, 270, 1491-1494 (1995).
27. KERPPOLA, T.K., LUK, D. and CURRAN, T., Fos is a preferential target of glucocorticoid receptor inhibition of AP-1 activity in vitro. Mol. cell. Biol., 13, 3782-3791 (1993).
28. LANDERS, J.P. and SPELSBERG, T.C., New concepts in steroid hormone action: transcription factor protooncogenes and the cascade model for steroid regulation of gene expression. Crit. Rev. Eukaryotic Gene Expr., 2, 19-63 (1992).
29. LI, X.S., CHEN, J.C., SHEIKH, M.S., SHAO, Z.M. and FONTANA, J.A., Retinoic acid inhibition of insulin-like growth factor stimulation of c-fos mRNA levels in a breast carcinoma cell line. Exp. Cell Res., 211, 68-73 (1994).
30. LIAN, J.B., STEIN, G.S., BORTELL, R. and OWEN, T.A., Phenotype suppression: a postulated molecular mechanism for mediating the relationship of proliferation and differentiation by Fos/Jun interactions at AP-1 sites in steroid responsive promoter elements of tissue-specific genes. J. cell. Biochem., 45, 9-14 (1991).
31. LIM, J.S., LY, A., BHIMANI, R., FRENKEL, K. and TROLL, W., The chemopreventative agent tamoxifen causes apoptosis. Proc. Amer. Assoc. Cancer Res., Abstract 3693 (1994).
32. MUELLER, H., LIU, R., DAVID, F. and EPPENBERGER, U., Selective modulation of protein kinase A and protein kinase C activities in epidermal growth factor (EGF)-stimulated MCF-7 breast cancer cells. Biol. Chem., 378, 1023-1029 (1997).
33. NATIONAL COORDINATING GROUP OF BREAST SCREENING PATHOLOGY, Pathology Reportig in Breast Cancer Screening. In: NHSBSP Publication, 3, pp. 41-42, Sheffield (1995).
34. NEPHEW, K.P., POLECK, T.C., AKCALI, K.C. and KHAN, S.A., The antioestrogen tamoxifen induces c-fos and jun-B but not c-jun or jun-D protooncogenes in the rat. Endocrinology 133, 419-422 (1993).
35. NICHOLSON, R.I., BOUZUBAR, N., WALKER, K.J., MCCLELLAND, R., DIXON, A.R., ROBERTSON, J.F.R., ELLIS, I.O. and BLAMEY, R.W., Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Europ. J. Cancer, 27, 908-913 (1991).
36. NICHOLSON, R.I., GEE, J.M.W., JONES, H., HARPER, M.E., WAKELING, A.E., WILLSHER, P. and ROBERTSON, J.F.R., erbB signalling and endocrine sensitivity of human breast cancer. In R.B. Lichtner and R.N. Harkins (eds.), Ernst Schering Research Foundation Workshop 19: EGF receptor in tumour growth and progression, pp. 105-128, Schering Publications, Berlin (1997).
37. NICHOLSON, R.I., MCCLELLAND, R.A., FINLAY, P., EATON, C.L., GULLICK, W.J., DIXON, A.R., ROBERTSON, J.F.R., ELLIS, I.O. and BLAMEY, R.W., Relationship between EGFR, c-erbB-2 protein expression and Ki-67 immunostaining in breast cancer and hormone sensitivity. Europ. J. Cancer, 29A, 1018-1023 (1993).
38. OLIVE, M., KRYLOV, D., ECHLIN, D.R., GARDNER, K., TAPAROWSKY, E. and VINSON, C., A dominant-negative to activation protein-1 (AP-1) that abolishes DNA binding and inhibits oncogenesis. J. biol. Chem., 272, 18586-18594 (1997).
39. PATTERSON, J.S., Clinical aspects and development of antioestrogen therapy: a review of the endocrine effects of tamoxifen in animals and man. J. Endocrinol., 89, 67-75 (1981).
40. PFAHL, M., Nuclear receptor/AP-1 interaction. Endocrinol. Rev., 14, 651-658 (1993).
41. PHILIPS, A., CHALBOS, D. and ROCHEFORT, H., Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J. biol. Chem., 268, 14103-14108 (1993).
42. PINDER, S.E., WENCYK, P., SIBBERING, D.M., BELL, J.A., ELSTON, C.W., NICHOLSON, R.I., ROBERTSON, J.F.R., BLAMEY, R.W. and ELLIS, I.O., Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Brit. J. Cancer, 71, 146-149 (1995).
43. PRESTON, G.A., LYON, T.T., YIN, Y. LANG, J.E., SOLOMON, G., ANNAB, L., SRINIVASAN, D.G., ALCORTA, D.A. and BARRETT, J.C., Induction of apoptosis by Fos protein. Mol. cell. Biol., 16, 211-218 (1996).
44. ROBERTSON, J.F.R., Oestrogen receptor: a stable phenotype in breast cancer. Brit. J. Cancer, 73, 5-12 (1996).
45. ROBERTSON, J.F.R., BATES, K., PEARSON, D., BLAMEY, R.W. and NICHOLSON, R.I., Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Brit. J. Cancer, 65, 725-730 (1992).
46. ROBINSON-BENION, C., LI, Y. and HOLT, J.T., Gene transplantation: combined anti-sense inhibition and gene replacement strategies. Leukemia, 8 (Suppl. 1), 152-155 (1994).
47. ROCHEFORT, H., Oestrogen and anti-oestrogen-regulated genes in human breast cancer. Ciba Found. Symp., 191, 254-268 (1995).
48. SKOOG, L., RUTQVIST, L.E. and WILKING, N., Analysis of hormone receptors and proliferation fraction in line-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta. Oncol., 31, 139-141 (1992).
49. SUTHERLAND, R.L., LEE, C.S., FELDMAN, R.S. and MUSGROVE, E.A., Regulation of breast cancer cell cycle progression by growth factor steroid and steroid antagonists. J. Steroid Biochem. mol. Biol., 41, 315-321 (1992).
50. TEETER, L.D., ECKERSBERG, T., TSAI, Y. and KUO, M.T., Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene PGPI reveals that the AP-1 site is essential for full promoter activity. Cell, Growth Differentiation, 2, 429-437 (1991).
51. WALKER, P.R., TESTOLIN, L., ARMATO, U., MARCEAU, H., GOURDEAU, H. and SIKORSKA, M., Modulation of apoptosis by oncogenes. In M. Tenniswood and H. Michna (eds.), Ernst Schering Research Foundation Workshop 14: Apoptosis in hormone-dependent cancers, pp. 103-122, Schering Publications, Berlin (1995).
52. WALKER, R.A. and COWL, J., The expression of c-fos protein in human breast. J. Pathol., 163, 323-327 (1991).
53. WANG, J.K., DAO, G. and GOLDFARB, M., Fibroblast growth factor receptors have different signalling and mitogenic potentials. Mol. cell. Biol., 14, 181-188 (1994).
54. WEBB, P., LOPEZ, G.N., UHT, R.M. and KUSHNER, P.J., Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell specific estrogen-like effects of antiestrogens. Mol. Endocrinol., 9, 443-456 (1995).
55. WEISER, M., BAKER, H., WESSEL, T.C. and JOH, T.H., Differential spatial and temporal gene expression in response to axotomy and de-afferentation following transection of the medial forebrain bundle. J. Neurosci., 13, 3472-3484 (1993).
56. WILLIAMS, M.R., TODD, J.H., ELLIS, I.O., DOWLE, C.S., HAYBITTLE, J.L., ELSTON, C.W., NICHOLSON, R.I., GRIFFITHS, K. and BLAMEY, R.W., Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Brit. J. Cancer, 55, 67-73 (1987).
57. WILLSHER, P.C., GEE, J.M.W., BLAMEY, R.W., NICHOLSON, R.I. and ROBERTSON, J.F.R., Changes in ER, PgR and pS2 protein during tumoxifen therapy for primary breast cancer. Breast Cancer Res. Treat., 41, 288 (1996).
58. WOSIKOWSKI, K., KUNG, W., HASMANN, M., LOSER, R. and EPPENBERGER, U., Inhibition of growth factor activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cells. Int. J. Cancer, 53, 90-97 (1993).